Unknown

Dataset Information

Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE.


ABSTRACT:

Objective

To examine the long-term changes in circulating B cell subsets and IgG levels at 5+ years of continuous belimumab treatment and their correlations with efficacy and safety measures.

Methods

This was a post hoc analysis of a continuation study (BEL112233; NCT00724867) of eligible US patients who completed the 76-week BLISS-76 Study (BEL110751; NCT00410384), with up to eight calendar-years of follow-up and median (IQR) belimumab exposure of 310 (209, 364) weeks. From week 76, patients initially randomised to intravenous belimumab 1 mg/kg or 10 mg/kg every 4 weeks in BLISS-76 continued to receive the same dose in the continuation study, while those initially randomised to placebo received belimumab 10 mg/kg intravenous every 4 weeks during continuation. All patients c

SUBMITTER: Struemper H 

PROVIDER: S-EPMC8823257 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature